BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

VOLUNTARY ANNOUNCEMENT
BIOCYTOGEN ANNOUNCES FDA IND CLEARANCE FOR PARTNER NEOK BIO'S NEOK002, ENTERING INTO AN IMPORTANT MILESTONE OF THE PARTNERSHIP

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**" or "**Biocytogen**") to provide its shareholders and potential investors with information in relation to the latest development of the Company.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that, the Company's partner, NEOK Bio, Inc. ("**NEOK Bio**") recently received clearance from the U.S. Food and Drug Administration ("**FDA**") of an investigational new drug ("**IND**") application for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate ("**ADC**") program for solid tumors therapy. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027.

This IND clearance marks an important milestone for NEOK002, which is built on a bispecific antibody originally discovered by Biocytogen and licensed in 2024, and further developed by NEOK Bio. According to NEOK Bio, NEOK002 is being advanced for solid tumors therapy and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone.

Dr. Shen Yuelei, chairman of the Board and chief executive officer of Biocytogen, said: "We are pleased to see one of our partnership projects reach this important stage of development. This milestone further validates the molecules quality, developability, and therapeutic potential of fully human bispecific antibodies discovered using our RenLite® platform, which features a common light chain design, and can efficiently support the research and development of innovative antibody drugs. We look forward to the continued clinical advancement of the project during the clinical stage."

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, March 26, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.